Trial Profile
A Phase 1/2 Clinical Trial to Study the Safety and Tolerability of MK-3475 + Pegylated Interferon Alfa-2b (PEG-IFN) and MK-3475 + Ipilimumab (IPI) in Subjects With Advanced Melanoma (MEL) and Renal Cell Carcinoma (RCC) (KEYNOTE 029)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 22 May 2022
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Peginterferon alfa-2b (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma; Renal cell carcinoma
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms KEYNOTE-029
- Sponsors Merck Sharp & Dohme Corp.
- 01 Jul 2021 Results (At data cutoff February 18, 2019; n=102 ) from cohort 1C, evaluating standard dose pembrolizumab with two other alternative ipilimumab regimens in advanced melanoma, published in the Clinical Cancer Research
- 05 Apr 2021 Status changed from active, no longer recruiting to completed.
- 15 Feb 2021 Planned End Date changed from 8 Feb 2021 to 11 Mar 2021.